Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications: transfection host （Nucleofection technology from Lonza）
DNA Profile （STR）: Amelogenin: X,Y
CSF1PO: 12,13
D13S317: 12
D16S539: 10
D5S818: 11,12
D7S820: 11,12
THO1: 5,7
TPOX: 8
vWA: 17
Age: 53 years adult
Gender: male
Comments: U266 cells have been reported to produce human IL-6.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1180: Nilsson K, et al. Established immunoglobulin producing myeloma （IgE） and lymphoblastoid （IgG） cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745
22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
產品型號：U266B1
